BeOne Medicines (ONC): Assessing Valuation After Sonrotoclax Study Success and TEVIMBRA European Approval

If you’ve been following BeOne Medicines (NasdaqGS:ONC), this week has offered a lot for investors to unpack. The company announced two pivotal updates: positive results from a Phase 1/2 study of sonrotoclax in relapsed/refractory mantle cell lymphoma and, just days earlier, European Commission approval for TEVIMBRA in early-stage non-small cell lung cancer. With both regulatory and clinical wins, it is no surprise the stock is commanding fresh interest among growth-focused investors and those evaluating oncology leaders with differentiated pipelines.

These milestones add momentum to what has already been an impressive stretch for BeOne. Shares have advanced roughly 79% over the past year, outpacing its pharmaceutical peers, and the last month alone brought gains of over 20%. While the company’s hematology franchise is expanding and headline revenue growth remains in the double digits, investors are watching to see whether this newest round of positive updates can sustain enthusiasm and justify the premium that has started to build in recent months.

With these developments in the mix, is the recent surge just the beginning, or is BeOne’s future potential already reflected in today’s price? Let’s dig into the numbers and see what the market might be missing.

Most Popular Narrative: 4.6% Undervalued

According to the most popular narrative, BeOne Medicines is currently undervalued by 4.6%, suggesting analysts see limited upside from today’s price based on their forward-looking assumptions.

BeOne's strong revenue growth (41% YoY in Q2; updated full-year guidance of $5 to $5.3B) is underpinned by rapid demand expansion for differentiated, best-in-class oncology therapies like BRUKINSA, supported by a growing, aging population and increased global healthcare spending. Both of these factors point to a sustainably expanding addressable market and future revenue growth.

Curious how experts calculate BeOne's next move? This valuation banks on aggressive profit turnarounds and margin leaps seen only in sector outliers. Ever wondered what bold growth projections are baked into the calculations? Peek inside the numbers that fuel this fair value call and see what Wall Street expects next.

Result: Fair Value of $363.30 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, continued dependence on a narrow product base and intensifying competition could still challenge BeOne's growth trajectory and future profitability.

Find out about the key risks to this BeOne Medicines narrative.

Another View: What Does the SWS DCF Model Say?

Looking at BeOne Medicines with our DCF model, the results tell a similar story. Shares trade well below what this approach calculates as fair value. Could the market be missing longer term upside?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out BeOne Medicines for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own BeOne Medicines Narrative

If these perspectives do not quite align with your own, or you would rather dig into the numbers yourself, you can craft your own analysis in just a few minutes. Do it your way

A great starting point for your BeOne Medicines research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Smart Investment Opportunities?

Do not let your research stop here. The market is packed with standout prospects, and using the Simply Wall Street Screener gives you an edge. Here are three unique investment paths you should not overlook:

• Boost your potential returns by targeting companies trading below their intrinsic worth with our list of undervalued stocks based on cash flows.
• Harness the power of artificial intelligence shaping healthcare advancements by scanning through innovative leaders in healthcare AI stocks.
• Secure steady income streams for your portfolio with handpicked choices in dividend stocks with yields > 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com